關(guān)鍵詞： Roche 纖維化 Galapagos
2013年3月9日訊 /生物谷BIOON/ --瑞士制藥巨頭Roche公司宣布,，退出與比利時制藥公司Galapagos公司在纖維化領(lǐng)域的合作協(xié)議,。而按照協(xié)議Roche公司也將向Galapago公司支付575萬歐元使得Galapago在該項(xiàng)目上的資金總額達(dá)到1600萬歐元,。
近年來纖維化疾病研究領(lǐng)域一直是各大醫(yī)藥公司的研究熱點(diǎn),，Biogen,、Bristol-Myers Squibb 和Novartis都在其中投入巨大精力,。（生物谷Bioon.com）
詳細(xì)英文報道：
Swiss drug giant Roche ($RHHBY) has exited an alliance with Belgium-based biotech Galapagos that focused on fibrosis discovery, leaving Galapagos hunting for another partner to hunt for compounds against fibrotic diseases. On its way out, Roche is forking over €5.75 million to Galapagos for the biotech's efforts through 2012, increasing the total payments from the alliance to €16 million, according to the company. "We regret that Roche ended the alliance due to a strategic change, but the good news is that all assets have returned to Galapagos," said Onno van de Stolpe, CEO of Galapagos, in a statement. Fibrotic diseases such as pulmonary fibrosis have been a hot area of drug development among biopharma players, including Biogen Idec ($BIIB), Bristol-Myers Squibb ($BMY) and Novartis ($NVS). There are no approved treatments for idiopathic pulmonary fibrosis in the U.S.
(責(zé)任編輯：yan.mao)
